Diana Hausman Sells 3,356 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) insider Diana Hausman sold 3,356 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $12.62, for a total transaction of $42,352.72. Following the transaction, the insider now directly owns 373,876 shares in the company, valued at approximately $4,718,315.12. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Zentalis Pharmaceuticals Stock Performance

NASDAQ:ZNTL traded up $0.09 on Thursday, hitting $12.52. The stock had a trading volume of 592,438 shares, compared to its average volume of 781,793. The stock has a market cap of $889.05 million, a P/E ratio of -2.74 and a beta of 1.82. The firm’s fifty day simple moving average is $13.70 and its two-hundred day simple moving average is $13.43. Zentalis Pharmaceuticals, Inc. has a 1 year low of $9.56 and a 1 year high of $31.46.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Tuesday, May 7th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.91. The company had revenue of $40.56 million for the quarter, compared to analysts’ expectations of $35.00 million. During the same quarter in the prior year, the company earned ($1.07) EPS. Equities research analysts predict that Zentalis Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. boosted its stake in shares of Zentalis Pharmaceuticals by 132.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,809 shares of the company’s stock valued at $36,000 after purchasing an additional 1,030 shares during the period. Quest Partners LLC purchased a new position in Zentalis Pharmaceuticals in the fourth quarter worth about $38,000. Tower Research Capital LLC TRC lifted its holdings in shares of Zentalis Pharmaceuticals by 252.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,615 shares of the company’s stock valued at $55,000 after purchasing an additional 2,589 shares in the last quarter. Exchange Traded Concepts LLC grew its position in Zentalis Pharmaceuticals by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 5,989 shares of the company’s stock worth $91,000 after purchasing an additional 1,519 shares during the period. Finally, OneAscent Financial Services LLC purchased a new stake in shares of Zentalis Pharmaceuticals during the 4th quarter valued at about $156,000.

Analysts Set New Price Targets

A number of research firms recently commented on ZNTL. HC Wainwright lowered their price target on shares of Zentalis Pharmaceuticals from $46.00 to $40.00 and set a “buy” rating on the stock in a research report on Wednesday. Wedbush upped their price target on shares of Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the stock a “neutral” rating in a report on Wednesday, February 28th. Finally, Stifel Nicolaus reduced their price objective on Zentalis Pharmaceuticals from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, Zentalis Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $37.14.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.